A global approach to antibiotic resistance

Picture Harpal Dhillon Chair RPS AMR groupBy Harpal Dhillon, Chair of the RPS Antimicrobial Expert Advisory Group

Bringing any new drug to market is a time consuming, costly and high-risk endeavour that typically takes 10 years, at an average development cost of about $1.3 billion U.S.

Even then, only one in five drugs tested in people is approved and reaches the market.  For antibiotics, the economic considerations are more challenging than for many other medical areas.  In addition to the unique scientific and regulatory challenges in antibiotic development, pricing and reimbursement do not reflect the true value of these life-saving drugs. Read more A global approach to antibiotic resistance